三一生物技术 plc 美股招股说明书（2026年6月23日版）

TRINITY BIOTECH PLC Secondary offering of up to33,752,429 American Depositary Shares This prospectus supplement updates and supplements the information contained in the prospectus dated June 16, 2026 (as may besupplemented or amended from time to time, the “Prospectus”), which forms a part of our Registration Statement on Form F-1, withinformation contained in our Report on Form 6-K, which was filed with the Securities and Exchange Commission on June 18, 2026 The prospectus, as it may be amended or supplemented from time to time, relates to the offer and resale by the Selling Shareholdersfrom time to time of up to 675,048,580 Ordinary Shares, represented by up to 33,752,429 ADSs. Our ADSs are listed for trading on the Nasdaq Global Select Market under the symbol “TRIB.” The last reported sale price of ourADSs on June 22, 2026 was $0.582. You should read the Prospectus, this prospectus supplement and any additional prospectus supplement or amendment carefully beforeyou invest in our securities. Our business and an investment in our ADSs involve significant risks. These risks are described under the caption “Risk Factors”beginning on page 4 of the Prospectus and any other risk factors contained in any applicable prospectus supplement and in the Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securitiesor passed upon the accuracy or adequacy of this prospectus. Any representation to the contrary is a criminal offense. The date of this prospectus supplement is June 23, 2026. Washington, D.C.20549 FORM6-K For the month of June 2026 TRINITY BIOTECH PLC(Name of Registrant) IDA Business ParkBray, County. Wicklow, Ireland Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. This Form 6-K is being incorporated by reference into our Registration Statements on Form S-8 (File Nos. 333-182279, 333-195232 and 333-253070) and Form F-3 and (File Nos. 333-267160, 333-286020, 333-295842 and 333-280391). EXPLANATORY NOTE On June 23, 2026, the Company announced the launch of Trinovium, a new subsidiary focused on bringing healthcare‑grade fluidtechnology to the AI data centre liquid cooling market. A copy of the press release is filed herewith as Exhibit 99.1 EXHIBIT INDEX ExhibitDescription 99.1Trinity Biotech Launches Trinovium to Bring Healthcare-Grade Fluid Technology to the Rapidly Growing Multi-Billion SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed onits behalf by the undersigned, thereunto duly authorized. TRINITY BIOTECH PLCTrinity Biotech plc(Registrant) Exhibit 99.1 Contact:Trinity Biotech plcPaul Murphy(353)-1-2769800 RedChip Companies Inc.Dave Gentry, CEO(1)-407-644-4256(1)-800-RED-CHIP (733-2447)TRIB@redchip.com Trinity Biotech Launches Trinovium to Bring Healthcare-Grade Fluid Technology to the Rapidly Growing Multi-Billion DollarAI Data Center Liquid Cooling Market -New subsidiary will leverage existing US and EU manufacturing capacity, high-purity fluid expertise, and analytical technologies totarget liquid cooling performance and reliability in AI and high-performance computing environments -Data center liquid cooling market is projected to grow from $4 billion in 2026 to $27 billion by 2033 DUBLIN, Ireland and Wilsonville, Oregon (June 23, 2026) -Trinity Biotech plc (NASDAQ: TRIB), a commercial-stagebiotechnology company focused on human diagnostics and diabetes management solutions, today announced the launch of Trinovium,a dedicated subsidiary focused on advanced liquid cooling solutions and fluid intelligence systems for next-generation AI data centers.As escalating AI workloads increase compute density and heat generation, driving a rapid industry transition from air cooling toliquid-cooledinfrastructure,Trinovium will leverage Trinity's expertise in ultra-high-purity fluid manufacturing,analytical The data center liquid cooling market is projected to grow from $4 billion in 2026 to $27 billion by 2033, representing a 31.5% CAGR(2026, MarketsandMarkets)2, driven by increasing AI compute density and the growing adoption of liquid-cooled infrastructure.Independent industry research similarly projects sustained double-digit growth over the coming decade as conventional air-cooling approaches reach practical performance limits345. As Trinity Biotech’s operational transformation plan now reaches its final stages, the Company is able to redirect a portion of itsexisting United States and European Union manufacturing capacity—capable of producing millions of liters of high-precision fluids annually—to support Trinovium. This provides a capital-efficient path into the liquid cooling market while creating the potential foradditional operating leverage from existing assets. The Company has developed an initial direct-to-chip liquid cooling formulation designe